QC
LRMR icon

Quadrature Capital’s Larimar Therapeutics LRMR Stock Holding History

Quadrature Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,646
Closed -$220K – 1661
2025
Q4 		$220K Buy
57,646
+38,131
+195% +$148K ﹤0.01% 950
2025
Q3 		$62.9K Buy
+19,515
New +$73.2K ﹤0.01% 940
2025
Q2 		– Sell
-10,242
Closed -$21.9K – 1305
2025
Q1 		$21.9K Buy
+10,242
New +$32.4K ﹤0.01% 1027

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Quadrature Capital's LRMR Position: Q1 2026 in Review

Quadrature Capital sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 57,646 shares — an estimated $220K sold.

Quadrature Capital first reported a position in LRMR in Q1 2025 and held it in 3 quarters. The position peaked at $220K in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Quadrature Capital reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 57,646 Larimar Therapeutics shares in Q1 2026, an estimated $220K.
  • Quadrature Capital first reported a position in Larimar Therapeutics in Q1 2025 and held it in 3 quarters.
  • Quadrature Capital's Larimar Therapeutics position peaked at $220K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.